Skip to main content

Table 3 Treatment Related Toxicity

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

 

Grade 1/2

Grade 3/4

Toxicity

No.

%

No.

%

Hematologic

    

Neutropenia

3

14

9

41

Anemia

8

36

1

5

Febrile neutropenia

0

0

2

9

Leukopenia

3

14

4

18

Lymphopenia

4

18

4

18

Non-hematologic

    

Fatigue

21

95

1

5

Anorexia

17

77

7

32

Diarrhea

16

72

2

9

Mucositis

14

64

0

0

Rash

13

59

0

0

Liver enzyme elevation (AST)

12

55

0

0

Liver enzyme elevation (ALT)

9

41

0

0

Dizziness

9

41

0

0

Hypertension

7

32

0

0

Ocular irritation

7

32

0

0